Although the increased expression of ALDH may influence the response to treatment, other points must be taken into account, such as the molecular profile, both in the TSC population and in the non-TSC population, since the expression of EGFR, TRKB, KRAS, and HIF-1α, although not shown to be related to the tumorigenic abilities of TSCs, has been shown to influence the response to treatment. This evidence concerns the gene KRAS and tuberous sclerosis.